RWMA.MU Stock Analysis
RW
Uncovered
Rockwell Medical Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Rockwell Medical, Inc. is a biopharmaceutical company, which engages in the development of treatment for anemia, kidney disease, iron deficiency, and hemodialysis. The company is headquartered in Wixom, Michigan and currently employs 300 full-time employees. The firm is focused on providing products for patients suffering from blood disorders and diseases associated with the kidney. The company is developing and commercializing its technology platform, Ferric Pyrophosphate Citrate (FPC) for the transformative treatments for iron deficiency in multiple disease states. The company is also a supplier of hemodialysis concentrate products to kidney dialysis clinics. The firm has developed therapies namely Triferic and Triferic AVNU from its FPC platform. Its products Triferic (dialysate) and Triferic AVNU intravenous (IV), is a therapy indicated to replace iron and maintain hemoglobin in adult hemodialysis patients. Its Triferic AVNU, is an IV formulation of Triferic, for use by hemodialysis patients. The Company’s dialysis concentrates products include CitraPure Citric Acid Concentrate, RenalPure Liquid Acid Concentrate, RenalPure and SteriLyte Bicarbonate Concentrate and Ancillary products.